Zanubrutinib Plus Venetoclax as First-Line Therapy for CLL/SLL With Del17p

Preliminary data from a nonrandomized arm of the SEQUOIA trial, presented at the 2021 Annual Meeting of the American Society of Hematology, suggested that the combination of zanubrutinib and venetoclax was well-tolerated among treatment-na├»ve patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and the high-risk genomic abnormality del17p. Alessandra Tedeschi, MD, from … Continue reading Zanubrutinib Plus Venetoclax as First-Line Therapy for CLL/SLL With Del17p